Indian court returns Teva's Copaxone process infringement suit
This article was originally published in Scrip
Executive Summary
An Indian court has returned Teva's suit against Natco Pharma in a case concerning the alleged infringement of a process patent (Indian patent No190759) for its multiple sclerosis drug, Copaxone (glatiramer acetate) over jurisdiction issues. Teva was seeking to block exports of Natco's generic glatiramer to the US and other countries claiming an infringement of its process patent.